Vericel (NASDAQ:VCEL) Given "Sell (D+)" Rating at Weiss Ratings

Key Points

• Vericel's stock has been given a "sell (D+)" rating by Weiss Ratings, reissued in a recent report.
• Price targets for Vericel have been adjusted by various analysts, with Truist Financial lowering it from $46.00 to $41.00 while Zacks Research upgraded it to a "strong-buy" rating.
• The company's revenue increased by 20.1% compared to the same quarter last year, although it reported earnings per share of ($0.01) which was better than expectations.

Vericel (NASDAQ:VCEL - Get Free Report)'s stock had its "sell (d+)" rating reissued by analysts at Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

A number of other research firms have also commented on VCEL. Truist Financial cut their price target on Vericel from $46.00 to $41.00 and set a "buy" rating for the company in a report on Wednesday, October 15th. Zacks Research raised Vericel from a "hold" rating to a "strong-buy" rating in a report on Tuesday, October 14th. BTIG Research lowered Vericel from a "buy" rating to a "neutral" rating in a report on Wednesday, September 17th. Finally, Canaccord Genuity Group cut their price target on Vericel from $61.00 to $58.00 and set a "buy" rating for the company in a report on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $58.40.

Vericel Stock Performance

NASDAQ VCEL traded up $0.33 on Friday, hitting $36.32. 350,370 shares of the stock traded hands, compared to its average volume of 641,641. The business's fifty day moving average is $33.68 and its two-hundred day moving average is $38.10. Vericel has a 12 month low of $29.24 and a 12 month high of $63.00. The firm has a market capitalization of $1.83 billion, a price-to-earnings ratio of 299.92 and a beta of 1.39.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.03. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The business had revenue of $63.24 million during the quarter, compared to analyst estimates of $64.61 million. During the same period in the prior year, the company earned ($0.10) earnings per share. Vericel's revenue was up 20.1% compared to the same quarter last year. Analysts expect that Vericel will post 0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Vericel

Large investors have recently added to or reduced their stakes in the company. Ameritas Advisory Services LLC purchased a new stake in Vericel during the second quarter valued at about $30,000. CWM LLC raised its position in Vericel by 101.3% during the second quarter. CWM LLC now owns 1,379 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 694 shares in the last quarter. AlphaQuest LLC purchased a new stake in Vericel during the second quarter valued at about $60,000. GAMMA Investing LLC lifted its stake in shares of Vericel by 34.8% in the 1st quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company's stock valued at $129,000 after acquiring an additional 748 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its stake in shares of Vericel by 13.7% in the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company's stock valued at $125,000 after acquiring an additional 353 shares during the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.